How We Mark Time and How Time Marks Us
Dr. Gotlib discusses the road to approval of midostaurin for the treatment of advanced systemic mastocytosis.
A Randomized Trial in a Rare Cancer: Targeting CD30 in Cutaneous T Cell Lymphoma Yields Therapeutic Dividends
Dr. Roberts discusses a trial that looks at new therapies to be tested for the treatment of a rare cancer, cutaneous T cell lymphoma.
Drs. Badawy, Liem, and Thompson discuss several benefits, risks, and limitations of using health-related apps, focusing on hematology and oncology apps. They present a thorough study that includes recommendations of some of the best apps available, and a discussion of clinical benefits, cost-effectiveness, potential risks, and even legal concerns.
Dr. Alexis Thompson makes a thorough assessment of the latest clinical practice guidelines for sickle cell disease.
In June 2011, ASH hosted a workshop aimed at determining whether, based on available evidence, individuals with sickle cell trait are at increased risk for exertion- or heat-related illness or sudden death. The workshop also sought to determine if there was evidence-based support for requiring adult screening for sickle cell trait as a prerequisite for participation in athletics.
September-October 2017Volume 14, Issue 5
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology